JUSMEDICO ADVOKATANPARTSSELSKAB - CVR: 30728106

2023, DKK

03.06.2024

Bruttoresultat

984'

Primær drift

676'

Årets resultat

528'

Aktiver

1.628'

Kortfristede aktiver

1.526'

Egenkapital

1.269'

Afkastningsgrad

42 %

Soliditetsgrad

78 %

Likviditetsgrad

442 %

Resultat

03.06.2024

Årsrapport	2023 03.06.2024	2022 22.06.2023	2021 10.06.2022	2020 25.06.2021	2019 20.04.2020	2018 04.06.2019	2017 31.05.2018	2016 12.06.2017	2015 29.04.2016
Nettoomsætning	1.518.157	1.618.546	2.071.121	3.145.265	3.028.683	3.017.345	2.041.313	2.246.763	1.765.763
Bruttoresultat	983.950	1.040.083	1.387.977	2.246.547	2.008.167	2.160.556	1.395.824	1.498.312	1.212.951
Resultat af primær drift	676.241	327.867	577.888	702.104	990.103	1.043.022	2.959	555.518	304.336
Indtægter af kapitalandele (tilknyttede og associerede)	0	0	0	0	0	0	0	0	0
Finansielle indtægter	3.496	314	3.189	140	167	443.102	588.862	570.317	148.053
Finansieringsomkostninger	0	-7.236	-9.827	-19.391	-15.839	-22.393	-29.448	-7.128	-599
Andre finansielle omkostninger	0	0	0	0	0	0	0	0	0
Resultat før skat	679.737	320.945	571.250	682.853	974.431	1.463.731	562.373	1.118.707	443.276
Resultat	527.871	248.562	443.137	530.382	757.499	1.139.658	435.037	813.743	283.969
Forslag til udbytte	-300.000	-800.000	-400.000	-530.382	-1.249.298	-1.139.658	-105.800	-103.400	-101.200

Aktiver

03.06.2024

Årsrapport	2023 03.06.2024	2022 22.06.2023	2021 10.06.2022	2020 25.06.2021	2019 20.04.2020	2018 04.06.2019	2017 31.05.2018	2016 12.06.2017	2015 29.04.2016
Kortfristede varebeholdninger	0	0	0	0	0	0	0	0	0
Kortfristede tilgodehavender fra salg og tjenesteydelser	856.272	1.454.058	2.180.760	1.586.502	1.195.222	1.289.227	2.556.554	2.199.015	1.780.072
Likvider	670.160	302.635	198.664	1.007.718	1.747.951	2.973.722	512.209	233.030	310.725
Kortfristede aktiver	1.526.432	1.756.693	2.379.424	2.594.220	2.943.173	4.262.949	5.680.588	5.352.226	3.980.007
Immaterielle aktiver og goodwill	0	0	0	0	0	0	0	0	235.998
Finansielle anlægsaktiver	31.438	28.500	105.104	105.967	103.466	101.863	14.708	14.708	14.708
Materielle aktiver	70.223	122.889	44.521	111.302	416.448	496.347	0	0	0
Langfristede aktiver	101.661	151.389	149.625	217.269	519.914	598.210	14.708	14.708	250.706
Aktiver	1.628.093	1.908.082	2.529.049	2.811.489	3.463.087	4.861.159	5.695.296	5.366.934	4.230.713

Aktiver

03.06.2024

Passiver

03.06.2024

Årsrapport	2023 03.06.2024	2022 22.06.2023	2021 10.06.2022	2020 25.06.2021	2019 20.04.2020	2018 04.06.2019	2017 31.05.2018	2016 12.06.2017	2015 29.04.2016
Forslag til udbytte	300.000	800.000	400.000	530.382	1.249.298	1.139.658	105.800	103.400	101.200
Egenkapital	1.268.810	1.540.939	1.692.376	1.779.621	2.498.538	2.880.697	5.007.867	4.676.230	3.963.687
Hensatte forpligtelser	13.847	21.547	27.889	23.364	45.487	42.018	0	0	0
Langfristet gæld til banker	0	0	0	0	0	0	0	0	0
Anden langfristet gæld		0	0	0	0	0	0	0	0
Leverandører af varer og tjenesteydelser	48.868	48.200	52.076	72.352	67.621	66.457	240.386	91.271	4.606
Kortfristede forpligtelser	345.436	345.596	808.784	1.008.504	919.062	1.938.444	687.429	690.704	267.026
Gældsforpligtelser	345.436	345.596	808.784	1.008.504	919.062	1.938.444	687.429	690.704	267.026
Forpligtelser	345.436	345.596	808.784	1.008.504	919.062	1.938.444	687.429	690.704	267.026
Passiver	1.628.093	1.908.082	2.529.049	2.811.489	3.463.087	4.861.159	5.695.296	5.366.934	4.230.713

Passiver

03.06.2024

Nøgletal

03.06.2024

Årsrapport	2023 03.06.2024	2022 22.06.2023	2021 10.06.2022	2020 25.06.2021	2019 20.04.2020	2018 04.06.2019	2017 31.05.2018	2016 12.06.2017	2015 29.04.2016
Afkastningsgrad	41,5 %	17,2 %	22,9 %	25,0 %	28,6 %	21,5 %	0,1 %	10,4 %	7,2 %
Dækningsgrad	64,8 %	64,3 %	67,0 %	71,4 %	66,3 %	71,6 %	68,4 %	66,7 %	68,7 %
Resultatgrad	34,8 %	15,4 %	21,4 %	16,9 %	25,0 %	37,8 %	21,3 %	36,2 %	16,1 %
Varelagerets omsætningshastighed	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.	Na.
Egenkapitals-forretning	41,6 %	16,1 %	26,2 %	29,8 %	30,3 %	39,6 %	8,7 %	17,4 %	7,2 %
Payout-ratio	56,8 %	321,9 %	90,3 %	100,0 %	164,9 %	100,0 %	24,3 %	12,7 %	35,6 %
Gældsdæknings-nøgletal	Na.	4.531,1 %	5.880,6 %	3.620,8 %	6.251,0 %	4.657,8 %	10,0 %	7.793,5 %	50.807,3 %
Soliditestgrad	77,9 %	80,8 %	66,9 %	63,3 %	72,1 %	59,3 %	87,9 %	87,1 %	93,7 %
Likviditetsgrad	441,9 %	508,3 %	294,2 %	257,2 %	320,2 %	219,9 %	826,4 %	774,9 %	1.490,5 %

Resultat

03.06.2024

Gæld

03.06.2024

Årsrapport

03.06.2024

Nyeste:01.01.2023- 31.12.2023(offentliggjort: 03.06.2024)

Information om virksomhedens regnskabsklasse:The annual report of Jusmedico Advokatanpartsselskab for 2023 has been prepared in accordance with the provisions in the Danish Financial Statements Act applying to reporting class B entities and elective choice of certain provisions applying to reporting class C entities.

Beretning

03.06.2024

Dato for ledelsens godkendelse af årsrapporten:2024-05-27

Statement by Management on the annual report

Identifikation af den godkendte årsrapport:Today, the Executive Board has discussed and approved the annual report of Jusmedico Advokatanpartsselskab for the financial year 1 January - 31 December 2023.

Management's review

Beskrivelse af virksomhedens væsentligste aktiviteter:Jusmedico Law Firm Ltd. Advokatanpartsselskab (“Jusmedico”), is a specialist law firm providing legal services to the biotech, pharmaceutical, medical device and dentistry industries, life science investors and to suppliers and service providers thereto. The working areas of Jusmedico include research & development, pre-clinical test and clinical trial, data protection, production & supply, labelling & packaging, licensing, co-promotion & co-marketing agreements, agent and distribution agreements, as well as advertising & promotion advice. In addition Jusmedico renders legal advice to life science clients on third party liability insurance programs providing cover for clinical testing of investigational medicinal products and D&O programs. Internationally Jusmedico is a founding member of the BioLawEurope Alliance comprising a network of inde-pendent European law firms, please refer to http://www. jusmedico. com/biolaweurope, and individual attorneys licensed in one or more EU-, EFTA-, - and/or UK jurisdictions, providing legal services focusing on the same le-gal disciplines as Jusmedico. Further Jusmedico operates a representative office in New York, USA, see https://jusmedicolaw. com/ Jusmedico, which was established in May 2004, was transformed into a private limited company on 1 January 2007. Notwithstanding the transformation each attorney employed remained and remains personally liable for legal advice rendered under contract prior to and after the transformation. During 2023 Jusmedico has continued its co-operation with the members of its Advisory Board established in 2007. The Advisory Board comprises 9 professionals, including 7 specialists within the fields of research, patent-ing, clinical development, insurance, regulatory service, quality management, start-up tax planning and account-ing. These areas of expertise are especially relevant to Jusmedico's client portfolio, which comprises clients op-erating on a private commercial basis as well as on a non-profit public basis. The chairman of the Jusmedico Advisory Board is counselor at law Brian Marshall Hand, Esq. , Jusmedico Law Group, New York, who is also in charge of Jusmedico’s representative office in the USA. Also in 2023 Jusmedico assumed the role as secretary and treasurer of the BioLawEurope Alliance, which in 2023 held its 9th Annual Meeting in Vienna, Austria. The meeting was hosted by the Austrian member of the Alli-ance, Herbst Kinsky Rechtsanwalte, Vienna, represented by Dr. Sonja Hebenstreit, Rechtsanwaltin. In addition to activities via the BioLawEurope Alliance and referrals from the representative office in New York, Jusmedico is co-operating nationally with several Danish law firms, which on an ad hoc basis may be involved in assignments falling outside Jusmedico’s core competence areas. Jusmedico is primarily co-operating with Bugge Valentin, a full-service IP, marketing practices and tech boutique law firm in Denmark with highly ac-claimed litigation skills and track records. Bugge Valentin has also joined the BioLawEurope Alliance. The BioLawEurope Alliance and the Advisory Board initiatives enable co-operation across the boundaries of in-dividual professions and enable Jusmedico involving all relevant professionals in larger and/or long term client projects Jusmedico has continued to render services to new life science sector start-ups, including to assist them as their projects develop. In close co-operation with several business angles, Jusmedico has experienced a tendency to increase investments in the medical device sector balanced by a corresponding reduction in pharma and bio-tech. On this basis Jusmedico’s engagements in EU-supported business angle activities focusing on life science, incl. med tech, and financial service related investments, continues and has generated separately accounted for turnover. In spite hereof and in spite of the climate crisis, Russia’s continued aggression and war campaigns in Ukraine and the Gaza war, the 2023 turnover has been satisfactory. In 2024 the activity split will be continued. Jusmedico’s marketing activities primarily comprise participation in the BioLawEurope Alliance, homepage maintenance and participation in numerous networks and international conferences. In 2021, 2022 and 2023 Jusmedico was granted the Biotech Law Firm of the Year in Denmark award by INTL Global. Although Jusmedico has ceased contributing to the publication going forward, the historic publications and the awards continue to produce both domestic and international clients. Considering a staff reduction having taken place in 2021, management is satisfied with the Company's revenues amounting to MDKK 1,7 in 2023, against MDKK 1. 9 in 2022. Management proposes to the general meeting that dividends are paid to the shareholder for 2023 in the amount of TDKK 300.